Asthma and Allergy Associates, PC

Colorado Springs, Colorado 809907

4 studies enrolling now · 38 studies all time

What they study most

Allergic Rhinitis, Allergy, Peanut, Angioedema, Asthma, Atopic Dermatitis, COPD, Celiac Disease, Chronic Inducible Urticaria, Chronic Obstructive Pulmonary Disease, Chronic Spontaneous Urticaria, Chronic Spontaneous Urticaria (CSU), Dermatitis, Atopic

Studies at this site

• Study of DONQ52 in Active Celiac Disease — Recruiting now
• A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines — Recruiting now
• A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. — Recruiting now
• Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy — Recruiting now
• A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1) — Running, not enrolling
• Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts — Completed
• A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines — Running, not enrolling
• Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet — Completed
• An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib — Running, not enrolling
• Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis — Completed
• Long-term Extension Study of Ligelizumab in Food Allergy — Stopped early
• Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) — Completed
• A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet — Completed
• Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy — Stopped early
• Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria — Completed
• A Study of Patients With Chronic Disease — Stopped early
• Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE) — Stopped early
• An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE) — Completed
• A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved — Completed
• A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor — Completed
• A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) — Completed
• A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA) — Completed
• Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2) — Completed
• A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America — Completed
• A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis — Completed
• Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global) — Completed
• Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients — Completed
• Evaluation of Two Doses of QVAR Versus Placebo by Breath Operated and Metered Dose Inhalers in Moderate Asthmatic Adolescents and Adults on a Stable Regimen of Inhaled Corticosteroids — Completed
• Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE) — Completed
• Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE — Completed
• Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE) — Completed
• Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema — Completed
• Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema — Completed
• Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE — Completed
• Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis — Completed
• An Evaluation Of PF-03715455 In Moderate To Severe Uncontrolled Asthma — Stopped early
• A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older — Completed
• A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older — Completed